Swiss Biotech Report: Sunrise, not sunset, is the feeling of the hour
In 2022, the Swiss biotech industry "continued to demonstrate its resilience, adapting well to geopolitical upheavals and remaining a key driver of innovation for global healthcare". Swiss biotech companies generated revenues of CHF 6.8bn. Capital inflows amounted to more than CHF 1.3bn, of which CHF 780m went to listed companies and CHF 550m to private companies. These are some of the findings of the annual industry report published by the Swiss Biotech Association in collaboration with EY and presented at Swiss Biotech Day in Basel.
